FGF-1 is expressed in a high proportion of breast tumors. While overexpression of FGF-4 in the MCF-7 breast carcinoma cell line confers the ability to form spontaneously metastasizing tumors in ovariectomized nude mice without estrogen supplementation and in mice that receive tamoxifen pellets, the response of a cell to individual FGFs can be controlled at multiple levels, and the signi®cance of FGF-1 expression in human breast tumors is uncertain. To study the role of FGF-1, MCF-7 human breast cancer carcinoma cells, previously transfected with bacterial b-galactosidase, were retransfected with FGF-1 expression vectors. FGF-1 transfectants formed large, vascularized tumors in ovariectomized nude mice without estrogen supplementation as well as in mice that received tamoxifen pellets. Lymphatic and pulmonary micrometastases were detected as deposits of X-galstained cells as early as 17 days after cell inoculation whereas no metastases were detected in estrogensupplemented mice bearing similar-sized control tumors. When compared with controls, both clonal and polyclonal populations of FGF-1 overexpressing cells exhibited increased anchorage-independent growth and decreased population doubling times in estrogen-depleted or 4-hydroxytamoxifen containing medium. These results suggest that FGF signaling may be important in the transition of breast cancer cells from hormone-dependent to hormone-independent and from nonmetastatic to metastatic.
Introduction
Ectopic overexpression of epidermal growth factor receptor (EGFR), erbB-2 (HER-2/neu), heregulin, activated ras H , transforming growth factor b (TGFb), Insulin-like growth factor II (IGF-II) and ®broblast growth factor 4 (FGF-4, a.k.a. hst-1/K-FGF) can confer varying degrees of increased estrogen-independent in vitro or in vivo growth to the estrogenresponsive MCF-7 human breast carcinoma cell line Cullen et al., 1992; Daly et al., 1991; Arteaga et al., 1993; Sommers et al., 1990; Pietras et al., 1995; Benz et al., 1993; Liu et al., 1995; Miller et al., 1994) . These observations suggest that growth factor signal transduction can provide an alternative or interacting mitogenic stimulus to that supplied by estrogen. Although the MCF-7 cell line was originally derived from a metastatic site (Engel and Young 1978) , the tumors that develop in inoculated ovariectomized mice receiving estrogen supplementation rarely form spontaneous metastases and are noninvasive . Therefore this cell line is also a useful model for elucidating the mechanisms and steps involved in the progression to a metastatic phenotype. In the transfection studies which increased the tumorigenic phenotype, only FGF-4 overexpression was reported to also consistently increase the metastatic phenotype of MCF-7 cells . In addition to providing a mitogenic stimulus to breast cancer cells , FGF-4 can also stimulate endothelial cell growth (Delli-Bovi et al., 1988) . This additional phenotypic transition associated with FGF-4 overexpression suggests that the paracrine eects of FGF may also provide an avenue for tumor cell dissemination (Fidler and Ellis, 1994) . Although this study points out the potential alterations in the malignant potential that can result from FGF signal transduction in breast cancers, the signi®cance of the ®ndings are made uncertain by the fact that FGF-4 mRNA or protein is not consistently detected in human breast tumor specimens (Penault-Llorca et al., 1995; Lammie et al., 1991; Ding et al., 1992) .
FGF-4 is one of nine members of the FGF family of heparin-binding growth factors that have been described (Miyamoto et al., 1993; Tanaka et al., 1992; Basilico and Moscatelli, 1992) . Both FGF-1 (acidic) and FGF-2 (basic) are expressed in a signi®cant proportion of human breast tumor specimens (Yiangou et al., 1997; Bansal et al., 1995; Penault-Llorca et al., 1995; Anandappa et al., 1994; Smith et al., 1994; Ding et al., 1992) . The ®nding of these particular FGF family members in human breast cancer tissues could be indicative of their functional importance in the progression of this disease if either is capable of directing a phenotypic transition similar to that seen with FGF-4. Immunohistochemical and immunoblotting analyses suggest that the source of the FGF-2 expression in tumor tissues may often be the normal epithelia and myoepithelial component present in the samples (Yiangou et al., 1997; Visscher et al., 1995; Smith et al., 1994; Gomm et al., 1991; Ke et al., 1993) , although FGF-2 immunostaining can be observed in neoplastic cells as well (Yiangou et al., majority of the carcinoma tissues and adjacent normal tissues analysed by immunoblotting but is not detected in benign breast disease or normal reduction mammoplasty tissues. This suggests that an increase in the synthesis or deposition of FGF-1 may be an early feature in the development of breast cancer (Smith et al., 1994) .
FGF signaling is a complex process that can be regulated at multiple levels and it cannot be simply assumed that FGF-1 would have the same ability as FGF-4 to increase the malignant phenotype of breast cancer cells. Messenger RNA for each of the four high anity transmembrane tyrosine kinase FGF receptors (Givol and Yayon, 1992; Johnson and Williams, 1993) can be detected in breast cancer cell lines and primary breast cancer tissues Luqmani et al., 1992; Ding et al., 1992) and ampli®cation of three of the loci encoding these receptors occurs in 10 ± 15% of human breast cancers (Jaakkola et al., 1993; Jacquemier et al., 1994; Adnane et al., 1991) , further implicating FGF signaling as being important in pathogenesis or progression. The primary transcripts of the FGFRs have been shown to undergo dierential splicing to yield mRNAs encoding numerous secreted or cell bound isoforms (Givol and Yayon, 1992; Johnson and Williams, 1993; Johnson et al., 1991; Hou et al., 1991) which may dierentially modulate the extent of downstream signaling elicited by individual FGFs. Coexpression of more than one receptor is typically observed in breast cancer cell lines and tissues (Penault-Llorca et al., 1995; McLeskey et al., 1994; Lehtola et al., 1992) and additional complexity can be assumed to be generated by the participation of heterodimers in FGF signal transduction (Bellot et al., 1991) . Once internalized, various FGFs and FGFRs may dier in intracellular tracking to the nucleus where they may exert dierent eects (Renko et al., 1990; Zhan et al., 1992; Prudovsky et al., 1994) . Dierent FGFs have varying anities for heparan sulfate proteoglycans present within breast tumor tissues (Iozzo et al., 1994; Aviezer et al., 1994; Reich-Slotky et al., 1994) which function both as a reservoir for heparin-binding growth factors and in the formation of a ternary complex required for high anity receptor signaling (Spivak-Kroizman et al., 1994; Klagsbrun and Baird, 1991; Yayon et al., 1991; Kan et al., 1993) . Thus it is likely that the functional speci®city and extent of the biological response elicited by expression of a particular FGF family member is dependent upon the repertoire and number of high and low anity receptors expressed by a particular cell type as well as the levels and varieties of receptor isoforms expressed.
Recent ®ndings that exposure of MCF-7 cells to FGF-2 results in growth inhibition in vitro (Fenig et al., 1997) further underscores the necessity of individually determining the eects on growth of each FGF family member. To study the possible role of FGF-1 in the progression of breast cancer, we retransfected ML-20 cells, a clonal population of MCF-7 that had previously been transfected with the bacterial lacZ gene encoding bgalactosidase (b-gal) , with one of two expression vectors encoding FGF-1 with or without an appended secretory signal sequence. Compared to control transfected cells, FGF-1 transfectants show increased tumorigenicity and metastatic potential in vivo and enhanced anchorage-dependent and anchorage-independent growth in estrogen-depleted and antiestrogen-containing media. A feature of the FGF-1 induced tumors that was not previously observed in animals injected with FGF-4 transfected cells is the appearance of a large hemangiectasic,¯uid-®lled sac that surrounds the tumor cells. Thus, in our experimental system, FGF-1 transfection produces a similar, but not identical, phenotype to FGF-4 transfection.
Results
Transfection of a clone of b-gal expressing MCF-7 cells with FGF-1 expression vectors
As we and others have observed FGF-1 expression in malignant breast epithelial cells and tumor tissues (Bansal et al., 1995; Penault-Llorca et al., 1995; Anandappa et al., 1994; Smith et al., 1994; Ding et al., 1992) , we sought to determine the phenotypic eects of FGF-1 overexpression in a breast cancer cell line that does not produce detectable levels of FGF-1. Since one of the goals of this study included an examination of the eects of FGF-1 overexpression on the metastatic phenotype, ML-20 cells were chosen as a recipient. This is a well characterized, poorly metastatic clone of MCF-7 cells derived from a previous transfection with a vector containing the bacterial gene encoding b-gal . The inclusion of this marker increased the frequency with which metastases of FGF-4 overexpressing cells could be detected from 20 ± 30% to essentially 100% of injected animals. A second major goal of this study was to determine whether signal transduction mediated by FGF-1 had the same or similar eects on breast carcinoma cells as those mediated by FGF-4. We therefore chose expression vectors and recombinantly generated FGF-1 cDNAs which would optimize the production of biologically active forms of the protein. The ML-20 cell line was therefore separately retransfected with one of two FGF-1 eukaryotic expression vectors described below.
FGF-1 is a 154 amino acid protein which lacks a signal peptide and thus is not secreted via the endoplasmic reticulum/Golgi secretory pathway. Since an appended signal peptide is necessary for the full transforming eects of transfected FGF-1 to be observed in NIH3T3 ®broblasts (Forough et al., 1993) , one of our expression vectors contained an FGF-1 complementary DNA (cDNA) encoding the full-length 154 amino acid protein with sequences encoding the signal peptide of FGF-4 appended to the 5' end. This produces a protein product, hst-FGF-1 1 ± 154 , which is secreted when transfected into NIH3T3 ®broblasts (Forough et al., 1993) . The second vector contains a cDNA encoding a NH 2 -terminally truncated derivative of FGF-1 missing the ®rst 20 amino acids ). This corresponds to a proteolytic product of FGF-1 which possesses the full activity of the whole FGF-1 molecule (Strydom et al., 1986) but lacks the terminal 5' coding sequences that may form a stem-loop structure inhibitory for translation (Forough et al., 1993) . Both expression vectors used in this study confer resistance to G418.
Clonal and polyclonal populations of G418-resistant cells transfected with the expression vectors were FGF-1 overexpression in MCF-7 breast cancer cells L Zhang et al established and screened by Northern blotting for production of appropriately-sized mRNA ( Figure 1a ). As expected, mRNAs for full-length endogenous FGF-1 transcripts of 4.5, 3.4 and 2.0 kb which also contain untranslated sequences (Wang et al., 1989) , were not detected in the pooled polyclonal population of G-418 resistant ML-20 cells transfected with the empty vector nor in any of the FGF-1 transfectants. Dense bands of the shorter size predicted for polyA containing transcripts originating from the transfected FGF-1 21 ± 154 and hst-FGF-1 1 ± 154 cDNAs which only contain coding sequences (approximately 500 and 650 bp, respectively) were present in both clonal and polyclonal populations of both types of FGF-1 transfectants ( Figure 1a ). An additional band of 3.4 kb was seen only with RNA from FGF-1 transfected cells and most likely corresponds to a read-through transcript initiating from a second upstream CMV promoter which directs transcription of the G418-resistance gene . Western blotting was used to determine if the transfected mRNA was translated into an appropriately sized protein and whether FGF-1 could be detected in the conditioned media (CM) (Figure 1b) . The hst-FGF-1 1 ± 154 cDNA encodes 48 more amino acids than FGF-1 21 ± 154 but because the hst signal peptide (27 amino acids) would be cleaved when the hst-FGF-1 1 ± 154 protein is secreted, the ®nal secreted product would be a protein of approximately 17.5 kd. The translated product of the FGF-1 21 ± 154 cDNA would be expected to be 15.4 kd in size. These dierences in the sizes of the FGF-1 proteins produced by the two types of transfectants were observed. As expected, the recombinant FGF-1 protein produced by the hst-FGF-1 transfected cells was present in both the CM and in the cell lysates. Intracellular FGF-1 was seen in the lanes containing FGF-1 21 ± 154 transfected cell lysates but surprisingly, the CM of the FGF-1 21 ± 154 transfected cells contained substantial amounts of FGF-1 immunoreactivity. Based on what had been observed in rodent fibroblast and epithelial cells transfected with other signal peptide-less FGF-1 or FGF-2 constructs (Forough et al., 1993; Jouanneau et al., 1991; Blam et al., 1988; Rogelj et al., 1988) , the presence of appreciable levels of FGF-1 in the CM of the FGF-1 21 ± 154 transfected cells was an unexpected ®nding.
Subsequent experiments suggested that not all of the FGF-1 that might be present in either CM or lysates was removed by preadsorption to heparin sepharose beads prior to Western blotting (data not shown). To better quantitate the amount of FGF-1 present in CM and cell lysates, a solid-phase radioimmunoassay was developed. This asssay showed that while FGF-1 in media alone or media of the control pool was undetectable, 6.7 ± 14.9 ng/ml/10 6 cells of FGF-1 was detected in the CM of FGF-1 21 ± 154 transfectants and higher amounts of FGF-1 (52.4 ± 87.7 ng/ml/10 6 cells) were detected in CM from hst-FGF-1 1 ± 154 transfectants (Table 1) .
To determine if cell lysis might be contributing to detectable FGF-1 21 ± 154 in the CM, the amount of b-gal in paired CM and lysates from FGF-1 transfectants was quantitatively determined by a nonisotopic immunoassay. Since b-gal is an intracellular protein which would only be released by cell lysis, the ratio of FGF-1/b-gal could be used to provide an indication as to whether the FGF-1 21 ± 154 in media was there as the result of active secretion or as the result of cell lysis ( Table 2 ). As would be expected for an actively secreted protein, the ratio of FGF-1 to b-gal in the CM of hst-FGF-1 1 ± 154 transfectants was approximately 200 times higher than that in cell lysates while in the CM of FGF-1 21 ± 154 transfectants, the ratio was only 1.9 times higher than in cell lysates. Moreover, the amount of hst-FGF-1 1 ± 154 present in the CM was greatly reduced by pretreatment of the transfected cells with 0.5 mg/ml of brefeldin A, an inhibitor of endoplasmic reticulum-Golgi apparatus secretion pathway while the amount of FGF-1 21 ± 154 in the CM was unaected by treatment with either brefeldin A or 10 mM methylamine, an inhibitor of exocytosis (data not shown). We conclude that the FGF-1 present in the CM of FGF-1 21 ± 154 transfectants is primarily the result of cell lysis. However, we cannot exclude the possibility that an active secretory or release mechanism also contributes.
To con®rm the biological activity of the FGF-1 in the CM, we tested its ability to stimulate the incorporation of [ 3 H]thymidine into human umbilical vein endothelial cells (HUVEC). A neutralizing antibody against FGF-1 was used to con®rm the speci®city of the biological eect. Even at the high concentration used, the antibody was still only capable of inhibiting approximately 50% of the biological activity of recombinant FGF-1 in the portion of the dose response curve where a logarithmic response was detected (Figure 2a ). At this same concentration, the antibody also partially inhibited the activity in the CM of both types of FGF-1 transfectants (Figure 2b ). Despite the relatively poor neutralization activity of this FGF-1 antibody, the similarity in the extent of neutralization observed with either recombinant FGF-1 or CM con®rmed that the activity in the CM was due to the FGF-1 produced by the transfected cells. Media conditioned by both types of FGF-1 transfectants greatly stimulated the growth of HUVEC, increasing the cell number 2 ± 5 times in a dose-dependent manner when compared to media conditioned by control transfectants (data not shown). Thus the results of the Western blot, radioimmunoassay and HUVEC growth assays indicated that both types of FGF-1 transfected cells were producing sucient quantities of extracellular FGF-1 to expect full activation of the FGF receptors present on the surface of MCF-7 cells.
FGF-1 transfected cells are tumorigenic in ovariectomized athymic nude mice
We sought to determine the eects of FGF-1 overexpression on the tumorigenic phenotype. As described above, our results suggested that the release of the majority of the extracellular FGF-1 21 ± 154 likely occurs via cell death and lysis. As this may closely approximate the naturally occurring situation where tumor necrosis or apoptosis and subsequent release of FGF-1 may result in extracellular FGF-1 being available to the viable portions of the tumor, we focused on FGF-1 21 ± 154 transfectants for these in vivo studies and characterized a polyclonal pool of transfectants as well as a number of clonal isolates.
When ten million transfected cells were injected subcutaneously into the mammary fat pad of ovariectomized nude mice, the control transfectants produced no tumors in mice without estrogen supplementation, while FGF-1 21 ± 154 transfectants formed progressively growing tumors. The tumor incidence was 50 ± 84%, varying with the population used ( Table 3 ). The three clonal populations of FGF-1 transfected cells tested had a similar tumor incidence suggesting that these clones have reached a threshold level of expression sucient for tumorigenicity. Tumors were observed in 50% of the animals injected with the polyclonal FGF-1 pool, providing evidence that the tumor growth in the clonal lines is not simply due to clonal variation in the ML-20 parental cells. In ovariectomized mice that were otherwise untreated, the volume of tumors ranged from 126 ± 8736 mm 3 at 40 days after the inoculation. Thus, like the transfection with FGF-4, the transfection of MCF-7 cells with an FGF-1 expression vector was sucient to increase tumorigenicity and eliminate the requirement for supplemental estrogen for in vivo growth.
The most striking characteristics of tumors formed by the FGF-1 transfected MCF-7 cells was the high degree of neovascularization and the extreme permeability of newly formed blood vessels surrounding the tumor. During the ®rst 2 weeks following tumor cell injection, tumor nodules were pink and surrounded by visible blood vessels. Gradually, the developing tumor became purple and hematoma-like in appearance. The 87.7+6.4 52.4+5.9 a Cells were cultured in PRF-IMEM-5% CCS in 100 mm dishes to 90% con¯uence. The media was aspirated and 6 ml of PRF-IMEM-5% CCS with 50 mg/ml of heparin was added. After 16 h, the conditioned media were collected and the cells were counted with a Coulter counter. The concentration of FGF-1 was measured using a solid-phase radioimmunoassay as described in Materials and methods. b Values are normalized to 10 6 cells. Conditioned media (CM) were collected from 90% con¯uent cells cultured overnight in IMEM-1% FBS with 50 mg/ml of heparin. The cells were harvested with 10 mM EDTA-PBS and lysed by freezing and thawing. The concentration of FGF-1 was measured using a radioimmunoassay and b-galactosidase was measured by ELISA as described in Materials and methods. The values were normalized for 10 hematoma-like area frequently was larger than the solid tumor mass which was surrounded by a sac ®lled with bloody¯uid. This¯uid had the properties of an in¯ammatory exudate with a white blood cell count that was 18-fold higher and a platelet count that was 6.5-fold lower than values obtained with peripheral blood drawn from the same mice (data not shown). Two to three months later, if animals were not sacri®ced, the bloody¯uid was slowly absorbed, and in most animals, the sac became completely occupied by growing solid tumor. At this point, the external appearance of tumor changed from purple to white. In this aspect, the tumor phenotype produced by FGF-1 transfection was somewhat dierent from that observed with FGF-4 (McLeskey et al., 1993) . Evidence of FGF-1 induced neovascularization was seen within the hematoxylin and eosin-stained sections of formalin-®xed and paran-embedded material. Numerous endothelial cells and newly formed blood vessels ®lled with red blood cells were seen in the tumor tissues within the ®rst 2 months (Figure 3a ). With solidi®cation of the tumor lesion, there was an accompanying increase in the proportion of ®broblasts and connective tissue present in tumor sections ( Figure  3b ). Immunostaining of frozen tumor sections with a rat monoclonal antibody raised against the mouse PECAM-1 antigen (Millauer et al., 1994) con®rmed the presence of a large number of microvessels (data not shown) and an immunohistochemical study on formalin ®xed and paran embedded material with a rabbit antisera raised against an FGF-1 peptide (Spirito et al., 1991) con®rmed that 495% of tumor cells continued to express FGF-1 (Figure 4) . Although the immunohistochemistry assay should only be f Animals recieved tamoxifen pellets (5.0 mg/pellet, 60 day release) FGF-1 overexpression in MCF-7 breast cancer cells L Zhang et al considered as being semiquantitative, the intensity of the FGF-1 staining of the tumor cells in the xenografts approximated the strong FGF-1 immunostaining observed when the same antibody was used on sections from formalin-®xed and paran-embedded human breast tumor tissues (Figure 4) . Thus the levels of FGF-1 protein present in cancer cells in at least some cases of human breast carcinoma may be relatively high.
Eects of 17b-estradiol and tamoxifen on the in vivo growth of FGF-1 transfected cells
The ability of FGF-transfected MCF-7 cells to form tumors in ovariectomized nude mice suggests that FGF transfection mimics a step in the progression of breast carcinoma from estrogen-dependent to estrogen-independent. Therefore, we were interested in determining the growth responses of the FGF-1 transfected cells to estrogen or antiestrogen treatment of tumor-bearing mice, especially since we had previously observed that tumors produced by FGF-4 transfected cells were growth-stimulated by tamoxifen and growth-inhibited by estrogen (McLeskey et al., 1993) . Since the presence of the¯uid-®lled sac around some tumors, but not others, confounded tumor measurements before sacri®ce, data were analysed in two ways. First, tumor incidence was analysed by observing the presence or absence of a tumor at an injection site (Table 3) . Second, in some experiments, tumors were dissected from the¯uid-®lled sac at the time of sacri®ce and weighed ( Figure 5 ).
The eects of estrogen on the tumorigenicity of the FGF-1 transfected cell lines was somewhat variable. Tumor take seemed to be decreased by estrogen in clone 21, in which no tumors were observed in estrogen-treated animals (Table 3 ) and in the FGF-1 pool in which only one tumor was observed in estrogen treated animals. However, in one clone (clone 18), estrogen seemed to have a somewhat stimulatory eect when tumor weights with untreated mice were compared (P=0.07). Additionally, one clone (clone 10), produced tumors in which estrogen treatment had no eects on tumor weight at all, making this clone truly estrogen-independent in vivo ( Figure 5 ). Thus, tumor growth was not reliably stimulated by estrogen, despite the fact that these FGF-1 transfected cells remain estrogen-responsive in vitro.
The in vivo behavior of the FGF-1 transfected cells contrasted strongly with that of control transfectants. To rule out the possibility that the parental ML-20 cell line was no longer estrogen-dependent in vivo, a pooled polyclonal population of control transfected G418 resistant colonies was established and tested for tumorigenicity. Using this control ML-20 population, progressively growing tumors did not develop in Five mm thick deparanated sections of human breast cancer tissue were incubated with a 1 : 1000 dilution of rabbit anti-human FGF-1 peptide, followed by a biotinylated anti-rabbit secondary antibody and disclosure with peroxidase-coupled avidin followed by diaminobenzidine. Counterstain is methyl green. (Table 4) . However, the tumors that formed with estrogen for the control group were smaller at the same time point (mean tumor volume=162 mm 3 , range=75 ± 392 mm 3 at 6.5 weeks) than those seen following injection of untreated mice with a population of FGF-1 clone 18 cells (mean tumor volume=2553 mm 3 , range=110 ± 6318 mm 3 ) used as a basis for comparison in the same experiment. Tumor weights at the time of sacri®ce were also less in the controls (Figure 5c ).
Many separately maintained populations of the MCF-7 cell line are poorly tumorigenic even when estrogen is supplied (Noel et al., 1992; Zhang et al., 1995; McLeskey et al., 1993) . To increase the probability of tumor formation and thus increase the ability to con®rm the in vivo estrogen dependence of the control pool population in this experiment, the same animals were also injected on the opposite side with the same cells that had ®rst been mixed with Matrigel, an extract of reconstituted basement membrane components. As has been reported by others (Noel et al., 1993) , Matrigel coinjection had the eect of facilitating tumor growth (Figure 5c ). When coinjected with Matrigel, three of the ®ve mice that did not receive estrogen developed extremely small tumor nodules weighing less than 35 mg at the time of sacri®ce. Subsequent histological examination revealed that these small nodules were composed primarily of residual Matrigel with a few small nests of embedded tumor cells (data not shown). Matrigel had a much greater eect when the mice received estrogen pellets. The mean ®nal weight of these tumors was now slightly greater than the mean weight of tumors from untreated mice injected with FGF-1 clone 18 cells without Matrigel that was used as a basis for comparison in this experiment (Figure 5c ). This result again con®rmed the estrogen dependence of the parental ML-20 cell line for progressive tumor growth and indicated that overexpression of FGF-1 bypasses this requirement for estrogen.
In contrast to what was previously found with FGF-4 transfectants , tamoxifen treatment did not stimulate the growth or increase the incidence of tumors in any of the FGF-1 transfectants (Table 3 and Figure 5a,b) . Tumor formation in tamoxifen-treated mice is also observed when FGF-1 clone 21 cells are injected, but again, in this separate experiment, the tumor sizes are not statistically dierent from that seen in the untreated mice (McLeskey et al., 1996b ). There were only two , and had a weight at the time of sacri®ce of 20 mg. Both tumors were observed following Matrigel coinjection. In contrast, tumors in tamoxifen-treated animals were detected much more frequently when FGF-1 transfected cells were inoculated and these tumors generally grew to a larger size within the same or shorter timeframe (Table 3 and Figure 5a,b) . These results demonstrate that FGF-1 expression, like FGF-4 expression, consistently confers upon MCF-7 cells the capacity to form progressively growing tumors in antiestrogen-treated mice.
FGF-1 transfectants are metastatic
Distant spontaneous metastases were detected as deposits of 5-bromo-4-chloro-3-indoyl-b-D-galactoside (X-gal)-stained cells in 58 ± 70% of mice bearing tumors produced by FGF-1 transfected clonal cell lines and in 38% of the mice inoculated with the polyclonal pool of FGF-1 transfected cells. For all of the FGF-1 transfected cell lines, the major metastatic sites were the proximal lymph nodes and lungs with an incidence of 58% (99/170) and 63% (65/104), respectively. Although metastases could be found in brain, spleen, kidney and liver, the incidence was low and the sizes of the foci were small, consisting of only a few spots. In contrast, there were many metastases in the lung and lymph node (Figure 6a,b) . Since the blue spots of X-gal staining were initially detected under a dissecting microscope at low power, selected specimens were further con®rmed by histology with hematoxylin and eosin staining. These sections were found to contain metastatic tumor cells (Figure 6c,d) . Spontaneous metastases were found in axillary and inguinal lymph nodes and lung as early as 17 days after injection of FGF-1 transfected cells, the earliest time point tested. Figure 6 Spontaneous metastasis of FGF-1 transfected MCF-7 cells. The FGF-1 transfectants all express a high level of bgalactosidase with 95 ± 100% of the cells staining intensely blue when supplied with the chromogenic substrate, X-gal. bgalactosidase activity was used as a sensitive marker to trace metastatic tumor cells by staining the internal organs (lungs, axillary and inguinal lymph nodes, brain, liver, spleen, kidney) with X-gal as described . There was no evidence of micrometastases in any of the estrogen-treated mice bearing control pool tumors. In the same experiment, micrometastases could reliably be detected in the untreated ovariectomized mice bearing FGF-1 clone 18 tumors of smaller or similarsize as those produced in the estrogen-treated mice coinjected with Matrigel and control tranfected cells. This result ruled out the possibility that the absence of metastases in the estrogen-treated mice injected with this control population was due to a failure to reach a threshold tumor size required for metastasis. Thus we conclude that overexpression of FGF-1 facilitates the dissemination of tumor cells to distant sites and that this eect is in addition to its ability to facilitate tumor growth.
FGF-1 transfectants have an enhanced ability to grow in estrogen-depleted and antiestrogen-containing media under anchorage-dependent and independent conditions
As FGF-1 is a pleiotropic growth factor aecting endothelial as well as other mesodermally and neuroectodermally derived cells (Burgess and Maciag, 1989; Thomas et al., 1985; Folkman and Shing, 1992) , the eects observed on tumorigenicity may be related to paracrine eects associated with overexpression. However, FGFs can be mitogenic for breast epithelial cells (Valverius et al., 1990; Imagawa et al., 1994; Takahashi et al., 1989) Lehtola et al., 1992) . We therefore used anchorage-dependent and anchorage-independent in vitro growth assays in estrogen-depleted and antiestrogen-containing media to test whether FGF-1 overexpression had any autocrine eects on the growth of transfected cells.
Under anchorage-dependent growth conditions, the FGF-1 transfectants showed an enhanced growth rate in estrogen-depleted conditions compared to the control population. In PRF-IMEM-5% CCS without estrogen supplementation, the vector control pool population continued to grow for the ®rst 3 days but then slowed considerably between days three and nine (population doubling time=117 h). The initial growth of the control transfectants in estrogen-depleted conditions is similar to what has been described by others examining ER positive breast cancer cell lines and is referred to as a`steroid memory' eect (Glover et al., 1988) . In contrast, the FGF-1 transfected cells continued to grow exponentially for 9 days in estrogendepleted media with doubling times ranging from 85 h for the FGF-1 pool to 61 h for FGF-1 clone 10 ( Figure  7a ). FGF-1 transfectants remained responsive to estrogen in vitro and had approximately the same population doubling time as the control pool population when cultured in PRF-IMEM-5% CCS supplemented with 10 8 M estradiol (range 40.0 ± 47.3 h).
Addition of 10
77 M 4-hydroxytamoxifen to the PRF-IMEM-5% CCS did not have an additional inhibitory eect on either control or FGF-1 transfected cells indicating that the eect of FGF transfection was not due to an increased sensitivity to residual low levels of estrogen that might remain after stripping of the serum.
When the growth curves were statistically analysed, the dierence between any of the clonal lines of FGF-1 transfectants and the control pooled polyclonal population in PRF-IMEM-5% CCS was signi®cant (P=0.004). The FGF-1 pooled polyclonal population is likely to contain a mixture of both FGF-1 producing and non-producing cells. Despite this heterogeneity in the population, a statistically signi®cant dierence with the control pool was observed (P=0.002). This indicates that the dierence seen with FGF overexpression was not merely due to clonal dierences and indicates that FGF-1 can have autocrine growth stimulatory eects on ER+breast cancer cells under estrogen-depleted conditions.
To test whether FGF-1 transfectants remained sensitive to antiestrogens, a separate experiment was performed in which 10 77 M 4-hydroxytamoxifen was added to cells cultured in IMEM-10% FBS. This is a concentration of antiestrogen previously shown to be capable of inhibiting the growth stimulatory eects of the physiological concentrations of estrogen present in FBS . In this case, growth of both the control pool and the FGF-1 transfected cells was inhibited but the extent of inhibition was greater for the control pool (Figure 7b ). In all cell lines, the inhibition by 4-hydroxytamoxifen was reversed by treatment with 10 78 M 17b-estradiol. When the slopes of the growth curves in IMEM-10% FBS+10 77 M 4-hydroxytamoxifen were compared (Figure 7b) , there was again a statistically signi®cant dierence observed between the control pool transfectants and the FGF-1 transfectants, including the comparison with the FGF-1 polyclonal pool (P50.001). Thus in media containing FBS, FGF-1 transfected cells were signi®cantly less inhibited by 4-hydroxytamoxifen than the control pool.
In the anchorage-independent growth assays, FGF-1 transfected cells grew more actively than control transfectants in PRF-IMEM-5% CCS, forming 8 ± 14 times more colonies (P50.01, Figure 8a) . In PRF-IMEM-5% CCS, FGF-1 transfected cells remained responsive to estrogen forming 1.7 ± 2.2-fold more colonies when 10 78 M 17b estradiol was included in the agar. In PRF-IMEM-5% CCS, addition of 10 77 M 4-hydroxytamoxifen had little eect on soft agar colony formation of either FGF-1 or control transfectants again indicating that the enhanced growth of FGF-1 transfectants was not due to increased sensitivity to low levels of estrogen remaining in the serum. In this assay, the FGF-1 transfectants again showed reduced sensitivity to the presence of 10 77 M 4-hydroxytamoxifen in IMEM-10% FBS. Whereas the control pool showed an 86% reduction in the number of colonies when treated with 4-hydroxytamoxifen, the extent of inhibition with the FGF-1 transfected cells ranged from 56 ± 66% ( Figure  8b ). Once again, this dierence was statistically signi®cant even when the FGF-1 polyclonal pool was compared to the control pool (P=0.015).
Taken together, the results of this in vitro analysis indicate that the FGF-1 transfected cells remain responsive to estrogen despite the lack of a stimulatory eect of estrogen in vivo in most of the cell lines tested. They do however appear to possess a greater proliferative capacity than controls in estrogendepleted conditions. In addition, while they remain sensitive in vitro to 4-hydroxytamoxifen, the extent of inhibition is less than that seen in the control population. This is in apparent contrast to the lack of an in vivo eect seen when tamoxifen-treated mice were compared to untreated mice. However, since ovariectomized animals were used, the antiestrogenic eects of this agent would not be apparent in a situation where estrogen levels were extremely low. Nonetheless, these in vitro results point out that autocrine or intracrine eects of FGF-1 are capable of conferring a growth advantage under estrogen-deprived conditions.
Discussion
This study demonstrates that the overexpression of FGF-1 confers an increased malignant phenotype upon MCF-7 cells. We observed increased tumorigenicity in either ovariectomized nude mice without estrogen supplementation or in tamoxifen-treated mice and increased metastatic ability under all in vivo growth conditions. Changes in the in vitro phenotype included enhanced anchorage-dependent and independent growth in estrogen-deprived conditions and in the presence of the antiestrogen 4-hydroxytamoxifen.
Although FGF-1 is expressed in a large proportion of human breast tumor tissues (Bansal et al., 1995; Penault-Llorca et al., 1995; Anandappa et al., 1994; Smith et al., 1994; Ding et al., 1992) , the available evidence to date for a role of FGF-1 in breast tumorigenesis or progression is inconclusive and contradictory. Clinical analyses of the eects of FGF-1 expression are complicated by the observation of highly variable levels of expression in normal as well as malignant breast tissues (Bansal et al., 1995; Anandappa et al., 1994; Smith et al., 1994) . FGF-1 expression has been observed in almost 70% of the human breast cancers that were analysed by Western blotting. FGF-1 was expressed in normal areas adjacent to breast tumors but not in benign breast disease or reduction mammoplasties (Smith et al., 1994) . In apparent contrast with this study, a second report found higher levels of FGF-1 mRNA in benign breast disease tissue when compared to tumor tissue (Anandappa et al., 1994) and a third study, utilizing a much smaller sample size, found a lower frequency of FGF-1 positive tumors and high levels of FGF-1 protein in organoid cultures established from reduction mammoplasties using Western blotting. However, this study also found increased FGF-1 mRNA in normal tissue adjacent to breast tumors (Bansal et al., 1995) . This same study found no correlation with levels of FGF-1 expression and several parameters associated with poor prognosis, such as pathological stage, estrogen receptor or node status, but did show a positive correlation with clinical stage. Increased FGF-1 expression was associated with normal biopsies when compared with cancer; however, these samples included normal breast tissue adjacent to tumors which may have included areas of increased FGF-1 expression (Smith et al., 1994) . Our own studies show FGF-1 mRNA in 95% of breast tumors, as well as appreciable levels of FGF-1 protein expression localized to malignant breast epithelium in approximately 30% of a small sample of 23 breast tumors analysed by immunohistochemistry (Ding et al., 1992) .
Conclusive epidemiologic evidence for the prognostic signi®cance of FGF-1 expression in a particular subset of human breast tumors has not thusfar been rigorously demonstrated. This is due to the extent of heterogeneity within breast tumor tissues, the diculty in comparing gene expression between tissues which include variable numbers of nonexpressing cells, and the possibility that FGF-1 may have distinct eects on dierent subpopulations of either normal or tumor cells as a result of dierential expression of receptors and molecules involved in downstream FGF signal transduction events. Since our results clearly demonstrate that in a nude mouse models, FGF-1 expression can facilitate a signi®cant phenotypic change in breast tumor growth and metastatic potential, additional and more extensive clinical studies aimed at determining whether there is indeed a role of FGF-1 expression in determining patient outcome or resistance to tamoxifen therapy may be indicated.
FGF-1 eects on tumor growth and metastasis in this model may be the result of FGF-1 acting as a mitogen for the tumor cells themselves, paracrine eects on the host stroma, or a combination of both. FGF-1 overexpression had eects on in vitro growth phenotypes, suggesting autocrine or intracrine eects of FGF-1 overexpression in MCF-7 breast cancer cells L Zhang et al FGF were at least partially responsible for the tumor growth observed in vivo. Overexpression of FGF-1 also increased the ability of the tumor cells to disseminate to lymph nodes and lungs. Although the process of metastasis involves multiple processes of tumor-host interaction within the primary tumor and at the metastatic sites, the observed induction of metastasis might relate to the induction of angiogenesis in tumor tissue, thus increasing the opportunity for tumour cell invasion into the circulation. If a combination of eects are required to elicit the enhanced tumor growth and dissemination associated with FGF-1 overexpression, then expression of a combination of other growth factors that together have the same or similar autocrine and paracrine eects as FGF-1 might also result in a more malignant phenotype. Thus it is possible that a combination of growth factors or hormones yielding both a mitogenic stimulus to the tumor cells and an angiogenic stimulus to tumor endothelial cells might result in a phenotype similar to that seen with FGF-1 or FGF-4 overexpression. This possibility is curently being explored. If this is the case, then a mitogenic stimulus supplied by a non angiogenic FGF family member such as FGF-7 or ligand-independent activation of FGF receptors through cell adhesion molecules (Green et al., 1996) , heparan sulfate-containing proteoglycans (Gao and Goldfarb, 1995) or constitutively activating mutations (Webster and Donoghue, 1996; Neilson and Friesel, 1995) may make an association of FGF-1 overexpression with poor prognosis more dicult to establish if, as indicated by others, breast tumors are also producing dierent angiogenic factors Toi et al., 1994) .
Although the FGF-1 21 ± 154 cDNA does not encode a secretory signal peptide (Forough et al., 1993) , we observed no substantial dierence in either the in vitro or in vivo phenotypes elicited by FGF-1 overexpression when a limited number of cell lines transfected with the hst-FGF-1 1 ± 154 cDNA were analysed (unpublished data). Despite the lack of a signal peptide, both FGF-1 and FGF-2 are often found outside of cells and a number of suggestions for the active release or export of FGF-1 and FGF-2 via alternate mechanisms have been proposed (Jackson et al., 1992; Mignatti and Rifkin, 1991; Mignatti et al., 1991; Muthukrishnan et al., 1991) . Nonetheless, the bulk of our data indicates that cell death and lysis with release of intracellular FGF are likely to be the underlying mechanisms responsible for the majority of the FGF-1 detected in the CM of our FGF-1 21 ± 154 transfectants. Although large amounts of FGF-1 21 ± 154 could be detected in the CM, the levels of protein detected still only represent less than 3% of the amount of FGF-1 protein present intracellularly. Thus, a signi®cant portion of the FGF-1 21 ± 154 in the CM may simply be the result of the ecient expression vector used in this study and the death and lysis of a small fraction of the total cell population.
Many breast tumors contain areas of central necrosis. The results with our model raise the possibility that release of signal peptide-less FGF-1 as a result of cell death might have important growth stimulatory eects. The same phenotypic eects of FGF-1 overexpression were observed in the pooled polyclonal population of G-418 resistant cells which most likely consists of cells that are heterogeneous for levels of FGF-1 expression. In addition, we have previously demonstrated that FGF-4 overexpressing cells are able to support the growth and metastasis of b-gal expressing MCF-7 cells that do not overexpress FGF . Therefore, it is possible that paracrine support of tumor cells through release of FGF-1 by cell lysis would be an important mechanism for tumor growth. Others have reported that mixing a rat bladder carcinoma cell line with subpopulation of FGF-1 producing cells will reduce the time required for tumor formation and appearance of micrometastases. For this eect to be observed, as few as 0.001% of the total population need to produce the growth factor (Jouanneau et al., 1994) . The threshold level of FGF-1 production required for the phenotypic eects to be observed in our model remains to be determined. However, these results suggest that FGF expression in just a minor portion of the total population of cells present in breast tumor tissue may be sucient to drive tumor progression.
Our characterization of the eects of FGF-1 overexpression indicates that they are similar but not identical to that previously seen with FGF-4 transfected cells McLeskey et al., 1993) . Whereas we previously observed that FGF-4 transfected cells were stimulated by tamoxifen in vivo, we do not observe this with FGF-1 transfected cells. We also previously found that estrogen supplementation inhibited the growth of FGF-4 transfected cells. For FGF-1 transfected cells, tumor incidences were generally lower in estrogen-supplemented mice. This eect was not observed to the same extent in all clones examined and there were indications that one clone was instead stimulated by estrogen. In addition, we have recently identi®ed a separately transfected FGF-4 clonal cell line which is not growth stimulated by tamoxifen (McLeskey et al., 1996a and unpublished results) . Thus it is possible that clonal variation in levels of as yet unidenti®ed factors determines the responsiveness of FGF transfected cells to hormones and antihormones.
Recent evidence for a convergence of growth factor and steroid receptor signaling mechanisms (Kato et al., 1995; Aronica and Katzenellenbogen, 1993; IgnarTrowbridge et al., 1993) indicates that signaling through growth factors might enhance the activity of the estrogen receptor through MAP kinase phosphorylation of a serine residue within a transactivating domain of the receptor. This signaling may activate estrogen receptor in the absence of estrogen or increase the level of estrogen-dependent activation of genes mediated by estrogen receptor. ER phosphorylation through growth factor signaling may also enhance the agonist eects of tamoxifen (Kato et al., 1995) . This indicates that the potential interaction of estrogen receptor and growth factor receptor signaling is likely to be a complex process which can be dierentially regulated at a number of levels. This may be an underlying reason for the dierences observed among cell lines and in the phenotypes elicited by FGF-1 and FGF-4.
While FGF-4 transfected cells always produced solid tumors, the tumors produced by the FGF-1 transfected cells were frequently surrounded by a membranous sac ®lled with a bloody¯uid. Others have also observed an exaggerated angiogenic response upon histological examination of the tumors produced by hst-FGF-1 1 ± 154 transfected NIH3T3 cells (Forough et al., 1993) and this may be an underlying reason why the release of this particular FGF family member appears to be under unique forms of cellular regulation (Jackson et al., 1992) . This dierence between FGF-1 and FGF-4 transfectants in the extent or process of in vivo neovascularization indicates the signaling process mediated by these growth factors is not identical and that this dierence may result in diversity in the extent or types of secondary responses elicited by the various FGFs.
In summary, we have shown that transfection of FGF-1 into MCF-7 cells will confer estrogen-independent tumorigenicity, enhanced metastatic capability and reduced antiestrogen sensitivity in vitro. This study implies that FGF-1 released by tumor cells could play a critical role in the progression of breast cancer. If so, local administration of inhibitors of FGF production or inhibitors of the various steps or molecules involved in FGF signal transduction might have therapeutic value. The FGF-1 expressing cells MCF-7 cells and the FGF-1 related tumor model created in this study could be used for studying the interaction of growth factor receptor mediated pathways with steroid hormone receptor mediated pathways, in elucidating the steps involved in FGF signal transduction and for screening of anti-FGF-1 agents or testing drugs for antiangiogenesis and antimetastatic activity.
Materials and methods

Cell lines
The ML-20 cell line is a subclone of MCF-7 cells that stably expresses b-galactosidase . They were maintained in improved minimal essential medium (IMEM, Bio¯uids Inc., Rockville, MD) supplemented with 10% fetal bovine serum (FBS, Bio¯uids). Human umbilical vein endothelial cells (HUVEC) were passage 5 and were originally obtained from the American Type Culture Collection (ATCC, Rockville, MD). They were maintained in 20% FBS-IMEM supplemented with 30 mg/ml of endothelial cell growth supplement (Sigma, St Louis, MO). All the cells were cultured in a humidi®ed, 378C, 5% CO 2 incubator.
Construction of FGF-1 expression vectors and transfection of ML-20 cells
The plasmids sp-hst/KS3 : FGF-1 1 ± 154 -pMEXneo and FGF-1 21 ± 154 -pMEXNeo (Forough et al., 1993) were generously provided by T Maciag. The former vector contains a cDNA fusing the sequences encoding the signal peptide of FGF-4 to those encoding FGF-1 amino acids 1 ± 154. The second vector contains a cDNA encoding FGF-1 amino acids 21 ± 154, which retains the full biological activity of the complete protein (Burgess et al., 1985) . The coding regions for FGF-1 1 ± 154 coupled to the FGF-4 signal sequence or the coding region for FGF-1 21 ± 154 from these plasmids were inserted into the pCNCEB8 expression vector to allow utilization of the CMV immediate early promoter to drive transcription of the respective cDNA. Plasmids sp-hst/KS3 : FGF-1 1 ± 154 -pMEXneo and FGF-1 21 ± 154 -pMEXneo were digested with SalI, the ends ®lled in with Klenow fragment of DNA polymerase I and EcoRI linkers were added. Fragments of approximately 570 and 425 bp obtained after EcoRI digestion were separately inserted into the EcoRI site of pCNCEB8 producing one vector encoding FGF-1 1 ± 154 fused to the FGF-4 signal peptide (pCNChstFGF-1 1 ± 154 ) and a second vector encoding FGF-1 21 ± 154 lacking a signal peptide (pCNCFGF-1 21 ± 154 ). pCNCEB8 has a second CMV-driven transcription cassette containing sequences encoding the bacterial neomycin phosphotransferase conferring resistance to G-418. ML-20 cells were transfected with either pCNCFGF-1 21 ± 154 or pCNChstFGF-1 1 ± 154 using the method of Chen and Okayama (1987) , and individual clones were established by selection in media containing 800 mg/ml of G-418. In addition, pooled polyclonal populations of G-418 resistant colonies from each transfection, including one with the empty vector, were also established. Clonal and polyclonal populations of cells derived from pCNCFGF-1 21 ± 154 transfection are designated FGF-1 clone or pool whereas the clonal populations derived from pCNChstFGF-1 1 ± 154 transfection are designated hst-FGF-1 clones.
Northern analysis
Monolayers of transfected cells were washed with 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 PO 4 , pH 7.4 (phosphate buered saline, PBS) and total cellular RNA was extracted using TRIzol (Life Technologies, Gaithersburg, MD) according to the manufacturer's directions. The concentration, purity, and integrity of RNA were determined by spectrophotometry and ethidium bromide staining of samples electrophoresed in 1.0% agarose gels containing 0.38 M formaldehyde. Ten mg/lane of each total RNA were subjected to electrophoresis in a 1.0% agarose-0.38 M formaldehyde gel and transferred to a nitrocellulose membrane by capillarity. After baking at 808C for 2 h, the membrane was prehybridized for 3 h at 558C in 50% formamide, 0.8 M NaCl, 10 mM EDTA and 50 mM NaH 2 PO 4 , pH 7.4 (56SSPE), 0.5% Ficoll, 0.5% polyvinylpyrrolidone, 0.5% bovine serum albumin (2.56Denhardt's solution), 0.2% SDS, and 400 mg/ml sonicated salmon sperm DNA and 400 mg/ml yeast tRNA. The 32 P-UTP labeled FGF-1 riboprobe was made using the sense strand of the sequence of FGF-1 21 ± 154 as a template as described (Miller et al., 1994) . The membrane was hybridized in fresh prehybridization solution with added FGF-1 riboprobe and a 32 P-UTP labeled riboprobe for GAPDH (Miller et al., 1994) using 1610 6 d.p.m./ml of each probe at 558C overnight, washed with 15 mM NaCl, 1.5 mM sodium citrate (0.16standard saline citrate), 0.1% SDS at 658C three times for 30 min each, and autoradiographed overnight.
Western blot
Cells were cultured in 150 mm dishes to 80% con¯uence. After washing with IMEM, 12 ml of 1% FBS-IMEM was added. After 24 h, conditioned media (CM) was collected and cells were harvested with 10 mM EDTA in PBS and counted. One million cells were lysed in 1 ml of lysis buer (1% Nonidet P-40, 0.4% sodium deoxycholate, 50 mM Tris, 62 mM EDTA, 150 mM NaCl, 0.01 mM phenylmethylsulfonyl¯uoride, 0.5 mg/ml aprotinin, 0.5 mg/ml leupeptin and 0.5 mg/ml pepstatin, pH 7.5) at 48C for 10 min followed by centrifugation at 10 000 g. CM or cell lysates were incubated with 75 ml heparin-sepharose CL-6B beads (Pharmacia Biotech, Piscataway, NJ) with rotation at 48C overnight. Beads incubated with cell lysates were washed with lysis buer followed by centrifugation. All samples were washed three times with 20 mM Tris, 0.4 mM NaCl, 5 mM EDTA, pH 7.5, supplemented with proteinase inhibitors as above. FGF-1 was eluted with 30 ml of 26 reducing sample buer containing 250 mM Tris-HCl (pH 6.8), 10% b-mercaptoethanol, 2% SDS, 0.1% bromophenol blue and 30% glycerol (Enprotech, Natick, MA) and boiled for 3 min. Samples were loaded on a 14% polyacrylamide gel under reducing conditions and then electroblotted onto a nitrocellulose membrane. The membrane was blocked in 5% non-fat milk in 10 mM Tris, pH 7.0, 150 mM NaCl, 0.05% Tween 20 (TBST) buer at 48C overnight, and incubated with 1 mg/ml of rabbit anit-bovine FGF-1 polyclonal antiserum (Sigma, catalog no. F 5521, St Louis, MO), followed by 0.25 mg/ml of horseradish peroxidase (HRP) conjugated-goat antirabbit IgG with four washes with TBST between each step. The membrane was exposed to enhanced chemiluminescence substrate (Amersham, Arlington Heights IL), followed by immediate autoradiography.
Olympus SZH dissecting microscope. Some of the metastatic tissue samples were embedded in glycol methacrylate (Experimental Pathology Laboratory, Reston, VA) to preserve the blue color, sectioned, stained with hematoxylin and eosin, and photographed using an Olympus AH-2 microscope. For histologic examination, tumor tissues growing in nude mice for dierent time periods were ®xed in 10% phosphate-buered formalin and embedded in paran. Sections were made, stained with hematoxylin and eosin, and photographed using an Olympus AH-2 microscope.
Anchorage-dependent growth assay
Ten thousand cells/well of FGF-1 or control vector transfected cells in 1 ml IMEM with 10% FBS were plated in 24-well plates and allowed to attach overnight. Cells were stripped of estrogen by four changes of PRF-IMEM-5% CCS over a 2 day period. After stripping, the medium was replaced with fresh PRF-IMEM-5% CCS with appropriate treatment and representative wells were counted for day zero. Cells were harvested and counted on appropriate days using a Coulter automated cell counter. The growth curves were linearized by taking the logarithms of the cell counts. The growth curves were compared using F-tests based on the ®t of nested multiple linear regression models. Population doubling times were calculated using values obtained from the linear portion of the logarithmically plotted growth curve using the formula:
where N 2 is the number of cells at time t 2 and N 1 is the number of cells at time t 1 .
Anchorage-independent growth assay
Anchorage-independent growth assays were performed both in FBS-containing media with phenol red and in estrogen-depleted conditions using PRF-IMEM-5% CCS. For the latter, cells were stripped of estrogens as above prior to the assay. A 1.0 ml layer of 0.6% bottom agar in the appropriate media (with or without phenol red and containing either 10% FBS or 5% CCS) was placed into 35 mm dishes. Twenty thousand FGF-1 or control vector transfected cells were plated in 1 ml of 0.36% top agar in the appropriate media with added treatments. The dishes were incubated in a 378C, 5% CO 2 incubator for 10 ± 14 days, and colonies larger than 60 mm were quanti®ed using an Omnicon Image Analysis system.
